Latest news with #StromaForte
Hi Dubai
21-04-2025
- Health
- Hi Dubai
UAE Healthcare Breaks Ground with Historic Surgeries and Future-Ready Innovations in 2025
The UAE's healthcare sector is cementing its global leadership in 2025 through a string of landmark procedures and groundbreaking innovations across critical specialties. From historic surgeries to futuristic tech, the nation's medical institutions are redefining excellence. Kings College Hospital London Dubai recently performed the city's first liver transplant on a 13-month-old child, born with biliary atresia and a congenital heart defect. The complex case, supported by Al Jalila Foundation, highlights the depth of pediatric expertise now available locally. Cleveland Clinic Abu Dhabi made global headlines with the world's first remotely performed robotic-assisted focal therapy for prostate cancer. Using the Focal-One system, the procedure eliminated the need for invasive surgery. The hospital also carried out the UAE's first simultaneous robotic kidney transplant for donor and recipient using a single robot. Women's health saw a leap forward at Corniche Hospital with a minimally invasive egg collection and freezing procedure, offering a new frontier in fertility care. In regenerative medicine, the Abu Dhabi Stem Cells Centre reported promising results for Type 1 diabetes treatment using umbilical cord-derived stem cells. Major strides were also revealed at Arab Health 2025, where Emirates Health Services introduced two ambitious projects: artificial heart transplantation and pancreatic cell transplantation. Meanwhile, a clinical trial in Abu Dhabi on StromaForte for knee osteoarthritis showed strong potential in cell-based therapy. Looking ahead, M42 will bring heavy ion therapy—among the most advanced cancer treatments—to Cleveland Clinic Abu Dhabi. The hospital also launched a BioButton-powered remote monitoring programme for cancer patients during Abu Dhabi Global Healthcare Week, underscoring the UAE's commitment to personalized, tech-driven care. With AI, robotics, and precision medicine at the forefront, the UAE continues to reshape the future of global healthcare. News Source: Emirates News Agency
Al Etihad
18-04-2025
- Health
- Al Etihad
UAE healthcare sector advances in 2025 with rare surgeries, innovative treatments
18 Apr 2025 14:13 ABU DHABI (WAM)The UAE's healthcare sector has reinforced its leading position since the beginning of the year through a series of rare surgical procedures and the adoption of innovative treatments for critical illnesses, underscoring the high calibre of medical expertise across various UAE has transformed its healthcare system into a globally advanced model by investing in cutting-edge technologies such as artificial intelligence, therapeutic robots, and 3D printing to enhance the quality and sustainability of College Hospital London Dubai announced on Thursday the city's first liver transplant on an infant, a 13-month-old child, with the support of Al Jalila Foundation – the philanthropic arm of Dubai Health. The child was born with a rare condition known as biliary atresia, which caused his health to deteriorate despite an earlier surgical procedure to connect his liver to his intestines. He was also diagnosed with a congenital heart defect (atrial septal defect). The child was referred to King's College Hospital in Dubai by Al Jalila Children's Hospital, following the cardiac repair Clinic Abu Dhabi performed the world's first remotely conducted transcontinental robotic-assisted focal therapy for prostate cancer. Focal therapy is a non-invasive treatment that precisely targets a specific section of the prostate using ultrasound beams, eliminating the need for major surgery or radiation. The Focal-One system enhances this approach with a robotic arm that ensures precise and controlled ultrasound January, Cleveland Clinic Abu Dhabi also announced the UAE's first simultaneous robotic kidney transplant procedure for a donor and recipient using one Hospital has successfully performed a minimally invasive laparoscopic procedure for egg collection and freezing, a cutting-edge technique representing a significant leap forward in reproductive UAE's medical sector has also seen significant progress in implementing new and innovative treatments this year. In January, the Abu Dhabi Stem Cells Centre reported promising results in treating Type 1 diabetes using umbilical cord-derived mesenchymal stem cell (UC-MSC) Emirates Health Services (EHS) unveiled two innovative projects – an Artificial Heart Transplantation and an Pancreatic Cell Transplantation at Arab Health 2025 in April, the Department of Health – Abu Dhabi also completed a groundbreaking clinical trial in Abu Dhabi. The treatment, StromaForte, has shown a favourable safety profile and significant therapeutic potential for knee osteoarthritis, marking a significant step in evaluating cell-based therapies for degenerative joint diseases.M42, a leading global health technology company powered by AI, is meanwhile set to build a heavy ion therapy facility at Cleveland Clinic Abu Dhabi, bringing one of the most advanced and effective cancer treatment technologies to the Middle East. During Abu Dhabi Global Healthcare Week 2025, which concluded on Thursday, Cleveland Clinic Abu Dhabi also unveiled initiatives and new technologies to improve cancer patient care, including an innovative remote monitoring programme, using the BioButton wearable device, for cancer patients at the Fatima Bint Mubarak Centre.
Zawya
18-04-2025
- Health
- Zawya
UAE healthcare sector advances with rare surgeries, innovative treatments
ABU DHABI - The UAE's healthcare sector has reinforced its leading position since the beginning of the year through a series of rare surgical procedures and the adoption of innovative treatments for critical illnesses, underscoring the high calibre of medical expertise across various specialties. The UAE has transformed its healthcare system into a globally advanced model by investing in cutting-edge technologies such as artificial intelligence, therapeutic robots, and 3D printing to enhance the quality and sustainability of care. Kings College Hospital London Dubai announced on Thursday the city's first liver transplant on a 13-month-old child, with the support of Al Jalila Foundation – the philanthropic arm of Dubai Health. The child was born with a rare condition known as biliary atresia, which caused his health to deteriorate despite an earlier surgical procedure to connect his liver to his intestines. He was also diagnosed with a congenital heart defect (atrial septal defect). He was referred to King's College Hospital in Dubai by Al Jalila Children's Hospital, following the cardiac repair procedure. Cleveland Clinic Abu Dhabi performed the world's first remotely conducted transcontinental robotic-assisted focal therapy for prostate cancer. Focal therapy is a non-invasive treatment that precisely targets a specific section of the prostate using ultrasound beams, eliminating the need for major surgery or radiation. The Focal-One system enhances this approach with a robotic arm that ensures precise and controlled ultrasound delivery. In January, Cleveland Clinic Abu Dhabi also announced the UAE's first simultaneous robotic kidney transplant procedure for a donor and recipient using one robot. Corniche Hospital has successfully performed a minimally invasive laparoscopic procedure for egg collection and freezing, a cutting-edge technique representing a significant leap forward in reproductive medicine. The UAE's medical sector has also seen significant progress in implementing new and innovative treatments this year. In January, the Abu Dhabi Stem Cells Centre reported promising results in treating Type 1 diabetes using umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy. The Emirates Health Services (EHS) unveiled two innovative projects – an 'Artificial Heart Transplantation' and 'Pancreatic Cell Transplantation' at Arab Health 2025 in January. In April, the Department of Health – Abu Dhabi completed a groundbreaking clinical trial in Abu Dhabi. StromaForte has shown a favourable safety profile and significant therapeutic potential for knee osteoarthritis, marking a significant step in evaluating cell-based therapies for degenerative joint diseases. M42, a leading global health technology company powered by AI, is set to build a heavy ion therapy facility at Cleveland Clinic Abu Dhabi, bringing one of the most advanced and effective cancer treatment technologies to the Middle East. During Abu Dhabi Global Healthcare Week 2025, which concluded on Thursday, Cleveland Clinic Abu Dhabi also unveiled initiatives and new technologies to improve cancer patient care, including an innovative remote monitoring programme using the 'BioButton' wearable device, for cancer patients at the Fatima Bint Mubarak Centre.
Gulf Today
13-04-2025
- Health
- Gulf Today
Groundbreaking stem cell trial for knee osteoarthritis
The Department of Health - Abu Dhabi (DoH), has successfully completed a groundbreaking clinical trial in Abu Dhabi, in collaboration with Cellcolabs and Burjeel Holdings. Developed by Swedish biotech company Cellcolabs, StromaForte has shown a favourable safety profile and significant therapeutic potential for knee osteoarthritis, marking a significant step in evaluating cell-based therapies for degenerative joint diseases. The study evaluated the regenerative properties of Mesenchymal Stem Cells (MSCs), a type of stem cell known for its ability to reduce inflammation and repair and regenerate damaged tissues. Found naturally in the body, MSCs function as biological mediators by detecting areas of stress or injury and signalling the body to initiate its own healing process, rather than simply replacing damaged cells. In this clinical trial, patients received MSC injections derived from carefully screened healthy donors aged 18-30, directly into their affected knee joints. The goal was to confirm safety, ease pain, reduce inflammation and potentially repair cartilage damage, offering a potential alternative to surgery for those suffering from knee osteoarthritis. The clinical trial was led by Dr. Oussama Chaar, consultant Orthopaedic Surgeon and Dr. Veerabahu Muthusamy, specialist Orthopaedic Surgeon, and conducted at Burjeel Medical City and Burjeel Hospital from November 2023 to October 2024, where patients received a single dose of 50 million MSCs via ultrasound-guided injections. The results of the first phase (Phase I/II) of the trial have been encouraging, meeting its primary endpoint of safety confirmed by an independent safety monitoring board. Patients reported a significant reduction in pain levels, as measured by the Visual Analogue Scale (VAS), and an overall improvement in their quality of life, enabling them to move more comfortably and engage in daily activities with greater ease. Importantly, the treatment was well tolerated, with no serious adverse events reported. To further evaluate the therapy's efficacy, provide deeper insights into the therapy's impact, MRI scans have been conducted with detailed findings set to be presented at Abu Dhabi Global Health Week in April 2025. Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health - Abu Dhabi, highlighted, 'The successful completion of this clinical trial is a testament to Abu Dhabi's robust regulatory oversight and its growing appeal as a hub for cutting-edge medical research. WAM
Khaleej Times
12-04-2025
- Health
- Khaleej Times
Abu Dhabi successfully completes first groundbreaking stem cell trial for knee osteoarthritis
The Department of Health — Abu Dhabi (DoH), has successfully completed a groundbreaking clinical trial in Abu Dhabi, in collaboration with Cellcolabs and Burjeel Holdings. Developed by Swedish biotech company Cellcolabs, StromaForte has shown a favourable safety profile and significant therapeutic potential for knee osteoarthritis, marking a significant step in evaluating cell-based therapies for degenerative joint diseases. The study evaluated the regenerative properties of Mesenchymal Stem Cells (MSCs), a type of stem cell known for its ability to reduce inflammation and repair and regenerate damaged tissues. Found naturally in the body, MSCs function as biological mediators by detecting areas of stress or injury and signalling the body to initiate its own healing process, rather than simply replacing damaged cells. In this clinical trial, patients received MSC injections derived from carefully screened healthy donors aged 18-30, directly into their affected knee joints. The goal was to confirm safety, ease pain, reduce inflammation and potentially repair cartilage damage, offering a potential alternative to surgery for those suffering from knee osteoarthritis. The clinical trial was led by Dr. Oussama Chaar, consultant Orthopedic Surgeon and Dr. Veerabahu Muthusamy, specialist Orthopedic Surgeon, and conducted at Burjeel Medical City and Burjeel Hospital from November 2023 to October 2024, where patients received a single dose of 50 million MSCs via ultrasound-guided injections. The results of the first phase (Phase I/II) of the trial have been encouraging, meeting its primary endpoint of safety confirmed by an independent safety monitoring board. Patients reported a significant reduction in pain levels, as measured by the Visual Analogue Scale (VAS), and an overall improvement in their quality of life, enabling them to move more comfortably and engage in daily activities with greater ease. Importantly, the treatment was well tolerated, with no serious adverse events reported. To further evaluate the therapy's efficacy, provide deeper insights into the therapy's impact, MRI scans have been conducted with detailed findings set to be presented at Abu Dhabi Global Health Week in April 2025. 'The successful completion of this clinical trial is a testament to Abu Dhabi's robust regulatory oversight and its growing appeal as a hub for cutting-edge medical research. At the Department of Health – Abu Dhabi, we are committed to fostering a dynamic ecosystem that accelerates innovation while ensuring the highest standards of safety and ethics," Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health — Abu Dhabi, said. "By prioritising cell and gene therapies and regenerative medicine, we are paving the way for transformative treatments that improve patient outcomes and quality of life. These efforts reaffirm Abu Dhabi's position as a global leader in pioneering health innovations and shaping the future of precision medicine," she added. The clinical research was made possible through strong collaborations with global experts Cellcolabs, a member of Abu Dhabi's Hub71 global tech ecosystem, worked closely with DoH and Burjeel Medical City to bring this advanced stem cell treatment to patients in the UAE. Peter Ekstedt, CEO Cellcolabs UAE, commented, 'This clinical trial is a major milestone in Abu Dhabi's journey to becoming a global leader in regenerative medicine. At Cellcolabs, we are proud to contribute with our expertise in stem cells, to bring innovative, evidence-based solutions to patients suffering from knee osteoarthritis. By combining DOH's commitment to healthcare innovation with our advanced stem cell technology and know-how, we are paving the way for safer, more effective, and non-surgical treatments that can change the lives of thousands of patients suffering from OA in UAE.' Prof. Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, added, 'The success of the StromaForte trial is an exemplary showcase of Abu Dhabi's growing biotechnology sector. With continued research and development, stem cell therapy could transform osteoarthritis treatment, offering patients a non-surgical option for pain relief and improved mobility.'
